Zobrazeno 1 - 10
of 28
pro vyhledávání: '"William Harel"'
Autor:
Ana M A Domínguez, Sergio Arturo Sánchez-Guerrero, Rafael A Marín y López, Antonio Rodríguez-Ruiz, Eduardo Villanueva-Vidales, Angélica Gómez, Leopoldo Valiente-Banuet, Martha García-Torres, Amy S. Broulik, Sagrario Romero-Estrella, Eva D Calderón, William Harel, Lilia Infante-Ramírez, Jaime A Vázquez, Jeffrey M. Linnen
Publikováno v:
Transfusion. 46:111-117
BACKGROUND: West Nile virus (WNV) is the etiologic agent of an emerging disease in the Western Hemisphere that can be transmitted to humans by blood transfusion. WNV first appeared in the United States in 1999, in Canada in 2001, and in Mexico in 200
Publikováno v:
Melanoma Research. 11:325-335
Development of brain metastases despite extracerebral response to systemic immunotherapy is a common problem in melanoma patients. We have previously described a murine melanoma vaccine of interferon-gamma (IFNgamma)-treated, irradiated syngeneic B16
Autor:
William Harel, Malcolm S. Mitchell, Florence M. Hofman, Susan Groshen, Lin G. LeMay, Peter Goedegebuure, June Kan-Mitchell, Xiu‐Qing Huang
Publikováno v:
Annals of the New York Academy of Sciences. 690:153-166
Since 1985, we have conducted clinical trials with a therapeutic melanoma vaccine (melanoma theraccine). Mechanical lysates of two melanoma cell lines chosen for their complementary characteristics were combined with the adjuvant DETOX and injected s
Publikováno v:
Cancer Immunology Immunotherapy. 37:187-194
Twenty-five CD4+ cytotoxic T lymphocyte (CTL) clones were obtained from the peripheral blood or tumor tissues of melanoma patients undergoing active specific immunotherapy. Melanoma-reactive T cells were cloned by limiting dilution using either autol
Autor:
Lawrence Steinman, Malcolm S. Mitchell, June Kan-Mitchell, William Harel, Peter E. Liggett, Taizo Nitta, Marshall R. Posner, Jorge R. Oksenberg
Publikováno v:
Cancer Immunology Immunotherapy. 33:333-340
To study antitumor immunity in patients with choroidal melanoma, T cells were generated from the peripheral blood of choroidal melanoma patients by mixed lymphocyte/tumor cell culture (MLTC). Because autologous tumors are generally unavailable, an al
Autor:
Lucy Stevenson, William Harel, William D. Boswell, Grace E. Dean, James G. Jakowatz, Malcolm S. Mitchell, Susan Groshen
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(2)
PURPOSE To determine whether interferon alfa-2b (IFN-alfa; intron-A, Schering Corp, Kenilworth, NJ) can induce a remission in patients previously treated with active specific immunotherapy (therapeutic melanoma vaccine) without response. PATIENTS AND
Autor:
John W. Parker, Timothy L. Darrow, June Kan-Mitchell, Jorge R. Oksenberg, Peter S. Goedegebuure, Malcolm S. Mitchell, William Harel, Lawrence Steinman, Xiu Qing Huang
Publikováno v:
Cancer immunology, immunotherapy : CII. 37(1)
To study in vivo activated cytolytic T cells, CD8+ T cells clones were isolated from a melanoma patient (HLA A2, A11) treated with active specific immunotherapy for 5 years. CD8+ T lymphocytes, purified by fluorescence-activated cell sorting, were cl
Publikováno v:
Progress in Immunology Vol. VIII ISBN: 9783642514814
Over the past 6 years we have studied a therapeutic vaccine (“theraccine”) for human melanoma, while at the same time using this system as an immunological model with which to learn about the mechanisms underlying rejection of a human tumor. We h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3af2fa610dd622ac42d35d6b3440b58
https://doi.org/10.1007/978-3-642-51479-1_112
https://doi.org/10.1007/978-3-642-51479-1_112
Publikováno v:
Deutsche Gesellschaft für Chirurgie ISBN: 9783540565338
Die Entwicklung von Hirnmetastasen bei Patienten mit metastasiertem malignen Melanom, die unter aktiv-spezifischer Immuntherapie eine Tumorremission zeigten, bereitet ein besonderes therapeutisches Problem [1]. Es ist bisher nicht bekannt, ob die Imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b15069eb4a22ff776cb58cd12c124822
https://doi.org/10.1007/978-3-642-78122-3_21
https://doi.org/10.1007/978-3-642-78122-3_21
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(7)
PURPOSE Only a proportion of patients with disseminated melanoma who were immunized successfully with a therapeutic melanoma vaccine (theraccine) had a major clinical response. We investigated whether there was a correlation between their HLA phenoty